Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Japan.
Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Intern Med. 2022 Jun 1;61(11):1789-1793. doi: 10.2169/internalmedicine.8647-21. Epub 2022 Mar 26.
Secondary cold agglutinin syndrome (CAS) is autoimmune hemolytic anemia secondary to infections and lymphoid disorder. We here report the first Asian case of CAS secondary to novel coronavirus disease 2019 (COVID-19). A 72-year-old Japanese woman presented with a 2-week history of dyspnea and cough, and laboratory data revealed severe hemolytic anemia with a hemoglobin level of 4.7 g/dL. She was diagnosed with COVID-19, CAS, and monoclonal gammopathy of undetermined significance (MGUS). The anemia responded to corticosteroids administered for COVID-19 and required maintenance therapy. Although corticosteroids are not a standard therapy for CAS, they might be effective for CAS secondary to COVID-19 complicated with MGUS.
继发冷自身免疫性溶血性贫血(secondary cold agglutinin syndrome,CAS)是继发于感染和淋巴系统紊乱的自身免疫性溶血性贫血。我们在此报告首例新型冠状病毒病(COVID-19)继发 CAS 的亚洲病例。一名 72 岁日本女性因呼吸困难和咳嗽 2 周就诊,实验室数据显示严重溶血性贫血,血红蛋白水平为 4.7g/dL。她被诊断为 COVID-19、CAS 和意义未明的单克隆丙种球蛋白病(monoclonal gammopathy of undetermined significance,MGUS)。贫血对 COVID-19 给予的皮质类固醇治疗有反应,需要维持治疗。虽然皮质类固醇不是 CAS 的标准治疗方法,但对于 COVID-19 合并 MGUS 继发的 CAS 可能有效。